ClinicalTrials.gg
CompletedNCT04423393Updated Oct 8, 2024Results posted

Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection

A Phase 1 interventional study of VIR-3434 and Placebo in Chronic Hepatitis B, sponsored by Vir Biotechnology, Inc.. Completed at 24 sites in 7 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Vir Biotechnology, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies in Hepatitis B, Chronic with a site in Germany — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · Germany.

Enrollment
25th of 44
113 · median 137
Started
2020
with 3 others
Phase 1
6 of 53
none open now
Registered
40th of 53
by date

Among the 53 studies in Hepatitis B, Chronic with a site in Germany, this one is the 25th largest by enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2020, is one of 6 in phase 1, and was the 40th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 53 studies in Hepatitis B, Chronic with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Hepatitis B, Chronic with a site in Germany, or all of them as a file.
02

Study summary

This is a Phase 1 study in which healthy volunteers and participants with chronic HBV infection will receive VIR-3434 or placebo and will be assessed for safety, tolerability, pharmacokinetics (PK), and antiviral activity (only in participants with chronic HBV infection).

03

Conditions studied

  • Chronic Hepatitis B

Keywords

  • Hepatitis B Virus
  • Chronic Hepatitis B
  • HBV
  • Hepatitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Healthy Volunteers:

Inclusion Criteria:

  • Male or female age 18 - 55
  • Weight 40-125 kg

Exclusion Criteria:

  • Any chronic or acute medical condition that makes the volunteer unsuitable for participation
  • History or evidence of drug or alcohol abuse
  • History of allergic reactions to monoclonal antibodies or antibody fragments
  • History of anaphylaxis

CHB Patients:

Inclusion Criteria:

  • Male or female age 18 - 65
  • Weight 40-125 kg
  • Chronic infection for >/= 6 months

Exclusion Criteria:

  • Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation
  • Significant fibrosis or cirrhosis
  • History or evidence of drug or alcohol abuse
  • History of chronic liver disease from any cause other than chronic HBV infection
  • History of hepatic decompensation
  • History of anaphylaxis
  • History of allergic reactions to monoclonal antibodies or antibody fragments
  • History of immune complex disease
  • Active infection with , or hepatitis Delta virus
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    VIR-3434

    Biological: VIR-3434

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalVIR-3434

    VIR-3434 given by subcutaneous injection or intravenous infusion.

  • OtherPlacebo

    Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Treatment-emergent period, which is up to Week 24 in part A, and up to Week 8 in part B/C/D

  2. Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Up to 280 days post-dose

Secondary outcomes

  1. Cmax

    VIR-3434 Maximum Concentration in Serum

    Time frame: Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose

  2. Tmax

    VIR-3434 time of Cmax in Serum

    Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose

  3. AUClast

    VIR-3434 under the curve from time 0 to last measurable Time

    Time frame: Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose

  4. t1/2

    VIR-3434 apparent Elimination Half-life (t1/2) in serum

    Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose

  5. Vz/F

    VIR-3434 Volume of Distribution (SC only)

    Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose

  6. Vz

    VIR-3434 Volume of Distribution (IV only)

    Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose

  7. CL/F

    VIR-3434 Apparent serum clearance (SC only)

    Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose

  8. CL

    VIR-3434 Apparent serum clearance (IV only)

    Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose

  9. Number of Participants With ADA to VIR-3434

    Evaluate the immunogenicity of VIR-3434

    Time frame: Part A: Up to 168 days post-dose. Parts B-D: Up to 280 days post-dose

  10. Maximum Reduction of Serum HBsAg From Baseline (Day 1 Predose)

    HBsAg reductions at nadir and Week 4

    Time frame: Parts B-D: pre-dose and 1, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose

  11. Part D Only: Maximum Change of HBV DNA From Baseline (Day 1 Predose)

    HBV DNA reductions at nadir and Week 4

    Time frame: Parts B-D: pre-dose and 1, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose Parts B-D: pre-dose and 1, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose

  12. Titers (if Applicable) of ADA to VIR-3434

    Evaluate the immunogenicity of VIR-3434

    Time frame: Part A: Up to 168 days post-dose. Parts B-D: Up to 280 days post-dose

  13. Cmax

    VIR-3434 Maximum Concentration in Serum

    Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose

  14. AUClast

    VIR-3434 under the curve from time 0 to last measurable Time

    Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose

07

Results

Posted Oct 8, 2024

Participant flow

Participant flow — Overall Study
MilestonePart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart A Healthy Participants PlaceboPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart B: HBV Participants PlaceboPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart C: HBV Participants PlaceboPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SCPart D: HBV Participants Placebo
Started6666611666686666664
Entered extended follow up000000115501030000
Completed6666610666686646664
Not completed000001000000020000
Withdrew: Withdrawal by subject000001000000010000
Withdrew: Sponsor decision000000000000010000

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame:
Treatment-emergent period, which is up to Week 24 in part A, and up to Week 8 in part B/C/D
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart A Healthy Participants PlaceboPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart B: HBV Participants PlaceboPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart C: HBV Participants PlaceboPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SCPart D: HBV Participants Placebo
Number of Participants With Treatment-emergent Adverse Events (TEAEs)545436243322454263
PrimaryNumber of Participants With Clinical Laboratory Abnormalities
Time frame:
Up to 280 days post-dose
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities
ParticipantsPart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart A Healthy Participants PlaceboPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart B: HBV Participants PlaceboPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart C: HBV Participants PlaceboPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SCPart D: HBV Participants Placebo
ALT Grade 1011020001000100050
ALT Grade 2000001000000000000
ALT Grade 3000000000000000000
ALT Grade 4000000000000000000
Alkaline phosphatase Grade 1000001000121000000
Alkaline phosphatase Grade 2000000000000000000
Alkaline phosphatase Grade 3000000000000000000
Alkaline phosphatase Grade 4000000000000000000
AST Grade 1001022001100000120
AST Grade 2001000000000000000
AST Grade 3000000000000000000
AST Grade 4000000000000000000
Bilirubin Grade 1010000000000100000
Bilirubin Grade 2000100000000000000
Bilirubin Grade 3000000000000000000
Bilirubin Grade 4000000000000000000
SecondaryCmax

VIR-3434 Maximum Concentration in Serum

Time frame:
Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Reported as:
Geometric mean · Parts B-D: ng/mL
Cmax
Parts B-D: ng/mLPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SC
Cmax352 ± 27.0456 ± 152.85460 ± 36.519700 ± 56.9835 ± NA4750 ± 46.926100 ± 21.86000 ± 16.810800 ± 61.4
SecondaryTmax

VIR-3434 time of Cmax in Serum

Time frame:
Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Reported as:
Median · day
Tmax
dayPart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SC
Tmax7.00 (3.00 to 7.01)7 (3 to 7.00)3 (3.00 to 7.00).0833 (0.0417 to 0.292).0833 (0.0417 to 0.0847)6.90 (1.01 to 7.00)2.92 (1.00 to 6.88)5.44 (2.83 to 7.03)2.96 (2.11 to 6.97)3.98 (3.98 to 3.98)3.00 (2.95 to 3.94)2.99 (2.86 to 6.97)4.08 (0.0417 to 8.11)2.99 (2.91 to 3.15)
SecondaryAUClast

VIR-3434 under the curve from time 0 to last measurable Time

Time frame:
Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Reported as:
Geometric mean · Parts B-D: day*ng/mL
AUClast
Parts B-D: day*ng/mLPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SC
AUClast3130 ± 67.54150 ± 270.0106000 ± 72.3381000 ± 94.29540 ± NA39000 ± 133.0181,000 ± 964.49,270 ± 1,139.954,300 ± 122.7
Secondaryt1/2

VIR-3434 apparent Elimination Half-life (t1/2) in serum

Time frame:
Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Reported as:
Median · day
t1/2
dayPart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SC
t1/228.5 (27.0 to 30.3)24.3 (23.2 to 26.6)25.2 (21.6 to 28.7)24.0 (20.7 to 25.7)20.7 (19.3 to 22.7)3.57 (2.33 to 4.81)6.34 (6.34 to 6.34)7.94 (3.54 to 17.2)13.6 (5.96 to 16.0)3.82 (3.82 to 3.82)4.25 (2.48 to 6.02)8.36 (4.16 to 11.8)3.17 (3.17 to 3.17)1.99 (1.99 to 1.99)
SecondaryVz/F

VIR-3434 Volume of Distribution (SC only)

Time frame:
Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Reported as:
Geometric mean · mL
Vz/F
mLPart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SC
Vz/F12200 ± 15.210900 ± 27.310600 ± 27.79420 ± 12.94540 ± NA7410 ± 21.59830 ± 54.210300 ± NA6710 ± 27.47330 ± 22.55000 ± NA4880 ± NA
SecondaryVz

VIR-3434 Volume of Distribution (IV only)

Time frame:
Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose
Reported as:
Geometric mean · mL
Vz
mLPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IV
Vz7620 ± 26.37290 ± 24.6
SecondaryCL/F

VIR-3434 Apparent serum clearance (SC only)

Time frame:
Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Reported as:
Geometric mean · mL/day
CL/F
mL/dayPart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SC
CL/F295 ± 16.0308 ± 22.7292 ± 19.71950 ± 71.2496 ± NA697 ± 71.6653 ± 85.61860 ± NA1200 ± 111.2670 ± 32.81090 ± NA1700 ± NA
SecondaryCL

VIR-3434 Apparent serum clearance (IV only)

Time frame:
Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose
Reported as:
Geometric mean · mL/day
CL
mL/dayPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IV
CL244 ± 19.61950 ± 71.2
SecondaryNumber of Participants With ADA to VIR-3434

Evaluate the immunogenicity of VIR-3434

Time frame:
Part A: Up to 168 days post-dose. Parts B-D: Up to 280 days post-dose
Reported as:
Number · Participants
Number of Participants With ADA to VIR-3434
ParticipantsPart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SC
Number of Participants With ADA to VIR-343401100011221241
SecondaryMaximum Reduction of Serum HBsAg From Baseline (Day 1 Predose)

HBsAg reductions at nadir and Week 4

Time frame:
Parts B-D: pre-dose and 1, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Reported as:
Mean · IU/mL
Maximum Reduction of Serum HBsAg From Baseline (Day 1 Predose)
IU/mLPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart B: HBV Participants PlaceboPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart C: HBV Participants PlaceboPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SCPart D: HBV Participants Placebo
Nadir-1.30 ± 0.152-1.27 ± 0.666-1.96 ± 0.436-2.24 ± 0.353-0.04 ± 0.039-1.05 ± 0.598-1.28 ± 0.749-2.17 ± 0.252-0.06 ± 0.092-1.77 ± 0.931-1.83 ± 0.219-0.09 ± 0.039
Week 4-0.61 ± 0.400-0.38 ± 0.503-1.51 ± 0.245-1.69 ± 0.7660.02 ± 0.039-0.30 ± 0.382-0.16 ± 0.175-1.43 ± 0.711-0.01 ± 0.129-0.48 ± 0.608-0.37 ± 0.368-0.00 ± 0.016
SecondaryPart D Only: Maximum Change of HBV DNA From Baseline (Day 1 Predose)

HBV DNA reductions at nadir and Week 4

Time frame:
Parts B-D: pre-dose and 1, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose Parts B-D: pre-dose and 1, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Reported as:
Mean · IU/mL
Part D Only: Maximum Change of HBV DNA From Baseline (Day 1 Predose)
IU/mLPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SCPart D: HBV Participants Placebo
Nadir-1.44 ± 0.998-2.07 ± 1.007-0.12 ± 0.06
Week 4-0.70 ± 0.917-0.61 ± 1.1950.06 ± 0.472
SecondaryTiters (if Applicable) of ADA to VIR-3434

Evaluate the immunogenicity of VIR-3434

Time frame:
Part A: Up to 168 days post-dose. Parts B-D: Up to 280 days post-dose
Reported as:
Median · Median Titer
Titers (if Applicable) of ADA to VIR-3434
Median TiterPart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SC
Titers (if Applicable) of ADA to VIR-34340 (0 to 0)20 (20 to 40)160 (160 to 160)0 (0 to 0)0 (0 to 0)0 (0 to 0)40 (40 to 40)80 (40 to 160)240 (20 to 1280)120 (80 to 160)80 (80 to 80)20 (19 to 40)40 (20 to 2560)20 (20 to 320)
SecondaryCmax

VIR-3434 Maximum Concentration in Serum

Time frame:
Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose
Reported as:
Geometric mean · Part A: μg/mL
Cmax
Part A: μg/mLPart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IV
Cmax9.46 ± 27.432.1 ± 18.0105 ± 23.7363 ± 32.61060 ± 20.00
SecondaryAUClast

VIR-3434 under the curve from time 0 to last measurable Time

Time frame:
Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose
Reported as:
Geometric mean · Part A: day*µg/mL
AUClast
Part A: day*µg/mLPart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IV
AUClast302 ± 16.0964 ± 22.63060 ± 19.84010 ± 28.512300 ± 19.7

Adverse events

Collected over Treatment-emergent period, which is up to Week 24 in part A, and up to Week 8 in part B/C/D. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Healthy Participants 90 mg SC0/6 (0%)0/6 (0%)4/6 (66.7%)
Part A Healthy Participants 300 mg SC0/6 (0%)0/6 (0%)4/6 (66.7%)
Part A Healthy Participants 900 mg SC0/6 (0%)0/6 (0%)5/6 (83.3%)
Part A Healthy Participants 900 mg IV0/6 (0%)0/6 (0%)4/6 (66.7%)
Part A: Healthy Participants 3000 mg IV0/6 (0%)0/6 (0%)3/6 (50%)
Part A Healthy Participants Placebo0/11 (0%)0/11 (0%)6/11 (54.5%)
Part B: HBV Participants 6 mg SC0/6 (0%)0/6 (0%)0/6 (0%)
Part B: HBV Participants 18 mg SC0/6 (0%)0/6 (0%)1/6 (16.7%)
Part B: HBV Participants 75 mg SC0/6 (0%)0/6 (0%)2/6 (33.3%)
Part B: HBV Participants 300 mg SC0/6 (0%)0/6 (0%)3/6 (50%)
Part B: HBV Participants Placebo0/8 (0%)0/8 (0%)2/8 (25%)
Part C: HBV Participants 18 mg SC0/6 (0%)0/6 (0%)2/6 (33.3%)
Part C: HBV Participants 75 mg SC0/6 (0%)0/6 (0%)4/6 (66.7%)
Part C: HBV Participants 300 mg SC0/6 (0%)1/6 (16.7%)5/6 (83.3%)
Part C: HBV Participants Placebo0/6 (0%)0/6 (0%)4/6 (66.7%)
Part D: HBV Participants 75 mg SC0/6 (0%)0/6 (0%)2/6 (33.3%)
Part D: HBV Participants 300 mg SC0/6 (0%)0/6 (0%)6/6 (100%)
Part D: HBV Participants Placebo0/4 (0%)0/4 (0%)1/4 (25%)
Most frequent serious events
Most frequent serious events
EventPart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart A Healthy Participants PlaceboPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart B: HBV Participants PlaceboPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart C: HBV Participants PlaceboPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SCPart D: HBV Participants Placebo
Anaphylactic ReactionImmune system disorders0/60/60/60/60/60/110/60/60/60/60/80/60/61/60/60/60/60/4
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPart A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart A Healthy Participants PlaceboPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart B: HBV Participants PlaceboPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart C: HBV Participants PlaceboPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SCPart D: HBV Participants Placebo
HeadacheNervous system disorders2/63/61/61/61/62/110/60/61/62/62/80/60/64/60/61/63/61/4
ChillsGeneral disorders0/60/60/60/60/60/110/60/60/60/60/80/60/64/60/60/61/60/4
Injection site erythemaGeneral disorders0/63/61/60/60/60/110/60/60/61/60/81/60/60/60/60/61/60/4
ArthralgiaMusculoskeletal and connective tissue disorders0/60/60/60/60/62/110/60/60/60/60/80/61/61/62/60/63/60/4
FatigueGeneral disorders0/60/61/60/60/60/110/60/61/60/60/80/60/61/63/60/61/60/4
NauseaGastrointestinal disorders1/61/60/60/62/62/110/60/60/60/60/80/61/60/61/61/60/60/4
DizzinessNervous system disorders0/60/60/62/61/60/110/61/60/60/60/80/60/61/60/61/60/61/4
Upper Respiratory Tract InfectionInfections and infestations0/60/61/62/60/61/110/60/60/60/60/80/60/60/60/60/60/60/4
Injection Site PainGeneral disorders0/60/62/60/60/60/110/60/60/60/60/81/60/60/60/61/61/60/4
PyrexiaGeneral disorders0/60/60/60/60/60/110/60/60/60/60/80/61/60/60/60/62/60/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart A Healthy Participants PlaceboPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart B: HBV Participants PlaceboPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart C: HBV Participants PlaceboPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SCPart D: HBV Participants PlaceboTotal
Mean31.3 ± 11.9427.7 ± 7.9231.5 ± 9.7724.8 ± 4.5829.3 ± 12.9930.3 ± 10.7756.3 ± 5.7249.0 ± 6.9350.8 ± 8.3550.0 ± 8.8151.6 ± 6.3544.5 ± 10.8238.2 ± 8.3338.8 ± 8.9544.0 ± 8.5342.7 ± 7.7138.0 ± 6.1637.3 ± 8.5439.6 ± 12.37
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart A Healthy Participants PlaceboPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart B: HBV Participants PlaceboPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart C: HBV Participants PlaceboPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SCPart D: HBV Participants PlaceboTotal
Female43454600211322343249
Male23212566457344323264
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart A Healthy Participants PlaceboPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart B: HBV Participants PlaceboPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart C: HBV Participants PlaceboPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SCPart D: HBV Participants PlaceboTotal
Hispanic or Latino0021010000000000004
Not Hispanic or Latino56456953566655566497
Unknown or Not Reported10000113102011100012
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart A Healthy Participants PlaceboPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart B: HBV Participants PlaceboPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart C: HBV Participants PlaceboPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SCPart D: HBV Participants PlaceboTotal
American Indian or Alaska Native0000000000000000000
Asian11000032446500352036
Native Hawaiian or Other Pacific Islander0001210000000001016
Black or African American0000000101101010106
White33342733211156203251
More than one race0000000000000000000
Unknown or Not Reported22312300000000000114
Baseline HbsAg (IU/mL)
Baseline HbsAg (IU/mL)(log 10 IU/mL)Part A: Healthy Participants 90 mg SCPart A Healthy Participants 300 mg SCPart A Healthy Participants 900 mg SCPart A Healthy Participants 900 mg IVPart A: Healthy Participants 3000 mg IVPart A Healthy Participants PlaceboPart B: HBV Participants 6 mg SCPart B: HBV Participants 18 mg SCPart B: HBV Participants 75 mg SCPart B: HBV Participants 300 mg SCPart B: HBV Participants PlaceboPart C: HBV Participants 18 mg SCPart C: HBV Participants 75 mg SCPart C: HBV Participants 300 mg SCPart C: HBV Participants PlaceboPart D: HBV Participants 75 mg SCPart D: HBV Participants 300 mg SCPart D: HBV Participants PlaceboTotal
Mean——————1.94 ± 0.6172.78 ± 0.7112.55 ± 0.6932.59 ± 1.1502.24 ± 0.6383.34 ± 0.4554.12 ± 0.3533.71 ± 0.3753.18 ± 1.6523.79 ± 0.7294.29 ± 0.3054.15 ± 0.4963.17 ± 1.05
08

Study locations

24 sites
  • Investigative Site
    Essen, 45147, Germany
  • Investigative Site
    Frankfurt, 60590, Germany
  • Investigative Site
    Hannover, 30625, Germany
  • Investigative Site
    Leipzig, 04103, Germany
  • Investigative Site
    Mainz, 55131, Germany
  • Investigative Site
    Mannheim, 68167, Germany
  • Investigative Site
    Ulm, 89081, Germany
  • Investigative Site
    Hong Kong, Hong Kong
  • Investigative Site
    Busan, 47392, Korea, Republic of
  • Investigative Site
    Busan, 49241, Korea, Republic of
  • Investigative Site
    Seoul, 02841, Korea, Republic of
  • Investigative Site
    Seoul, 03080, Korea, Republic of
  • Investigative Site
    Seoul, 05505, Korea, Republic of
  • Investigative Site
    Seoul, 06273, Korea, Republic of
  • Investigative Site
    Auckland, 1010, New Zealand
  • Investigative Site
    Havelock North, 4130, New Zealand
  • Investigative Site
    Newtown, 6021, New Zealand
  • Investigative Site
    Tauranga, 3110, New Zealand
  • Investigative Site
    Bucharest, Romania
  • Investigative Site
    Singapore, 169608, Singapore
  • Investigative Site
    Singapore, 529889, Singapore
  • Investigative Site
    Birmingham, B15 2TT, United Kingdom
  • Investigative Site
    London, E1 2EF, United Kingdom
  • Investigative Site
    Manchester, M8 5RB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Oct 2022, 28 months.

Results were first posted in Oct 2024, 1 year 11 months after primary completion.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 28 months is above that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2020
First posted
Jun 9, 2020
StartActual
May 26, 2020
Primary completionActual
Oct 24, 2022
CompletionActual
Nov 25, 2022
Results first posted
Oct 8, 2024
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04423393
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
May 26, 2020
Primary completion
Oct 24, 2022
Completion
Nov 25, 2022
Results posted
Oct 8, 2024
Last update
Oct 8, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tobevibart

Start the discussion